EGF-ERBB signalling: towards the systems level.
Signalling through the ERBB/HER receptors is intricately involved in human cancer and already serves as a target for several cancer drugs. Because of its inherent complexity, it is useful to envision ERBB signalling as a bow-tie-configured, evolvable network, which shares modularity, redundancy and control circuits with robust biological and engineered systems. Because network fragility is an inevitable trade-off of robustness, systems-level understanding is expected to generate therapeutic opportunities to intercept aberrant network activation.
Citri
Ami
A
Department of Biological Regulation, the Weizmann Institute of Science, 1 Hertzl Street, Rehovot 76100, Israel.
Yarden
Yosef
Y
D000818:Animals; D004705:Endocytosis / Q000502:physiology; D004815:Epidermal Growth Factor / Q000378:metabolism*; D066246:ErbB Receptors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D025461:Feedback, Physiological; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D018739:Oncogene Proteins v-erbB / Q000235:genetics / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011487:Protein Conformation; D015398:Signal Transduction / Q000502:physiology*
D008024:Ligands; D018739:Oncogene Proteins v-erbB; D004815:Epidermal Growth Factor; D019869:Phosphatidylinositol 3-Kinases; D066246:ErbB Receptors